Upcoming clinical trials have explored the efficacy and safety of oral nonpeptidic GnRH antagonists, including Elagolix, Relugolix, and Linzagolix, for treating endometriosis-associated pain [188]. The gene discussed is GNRH1; the disease is endometriosis.